{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T15:56:41Z","timestamp":1781539001450,"version":"3.54.5"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s11095-026-04081-9","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T18:19:05Z","timestamp":1774462745000},"page":"1455-1470","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hospital-Compounded Birabresib Capsules for NUT Carcinoma: A Quality- and Risk-Based CMC Strategy"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9594-2516","authenticated-orcid":false,"given":"Maxime","family":"Annereau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois-Xavier","family":"Legrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Virginia","family":"S\u00e1nchez-Becerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Duperray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Denis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Sizun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylv\u00e8re","family":"Durand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Salomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Besse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"key":"4081_CR1","doi-asserted-by":"crossref","unstructured":"Huang QW, He LJ, Zheng S, Liu T, Peng BN. An Overview of Molecular Mechanism, Clinicopathological Factors, and Treatment in NUT Carcinoma. Biomed Res Int. 11 nov 2019;2019:1018439.","DOI":"10.1155\/2019\/1018439"},{"key":"4081_CR2","doi-asserted-by":"crossref","unstructured":"Lauer UM, Hinterleitner M, Horger M, Ohnesorge PV, Zender L. NUT Carcinoma\u2014An Underdiagnosed Malignancy. Front Oncol. 26 juill 2022;12:914031.","DOI":"10.3389\/fonc.2022.914031"},{"key":"4081_CR3","unstructured":"Zhang Y, Zhang Q, Hao Y, Luo J, Piao Y, Wang W, et al. International guidelines on the diagnosis and treatment of NUT carcinoma. The Innovation. 31 juill 2025;101068."},{"key":"4081_CR4","doi-asserted-by":"crossref","unstructured":"McLean-Holden AC, Moore SA, Gagan J, French CA, Sher D, Truelson JM, et al. NUT Carcinoma in a Patient with Unusually Long Survival and False Negative FISH Results. Head and Neck Pathol. 1 juin 2021;15(2):698\u2011703.","DOI":"10.1007\/s12105-020-01220-5"},{"issue":"4","key":"4081_CR5","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/s41571-025-00986-3","volume":"22","author":"J Luo","year":"2025","unstructured":"Luo J, Bishop JA, DuBois SG, Hanna GJ, Sholl LM, Stelow EB, et al. Hiding in plain sight: NUT carcinoma is an unrecognized subtype of squamous cell carcinoma of the lungs and head and neck. Nat Rev Clin Oncol avr. 2025;22(4):292\u2013306.","journal-title":"Nat Rev Clin Oncol avr"},{"key":"4081_CR6","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ejca.2021.01.018","volume":"146","author":"AD Pearson","year":"2021","unstructured":"Pearson AD, DuBois SG, Buenger V, Kieran M, Stegmaier K, Bandopadhayay P, et al. Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE. Eur J Cancer mars. 2021;146:115\u201324.","journal-title":"Eur J Cancer mars"},{"key":"4081_CR7","doi-asserted-by":"crossref","unstructured":"Stathis A, Zucca E, Bekradda M, Gomez-Roca C, Delord JP, de\u00a0La Motte Rouge T, et al. Clinical Response of Carcinomas Harboring the BRD4\u2013NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015\/MK-8628. Cancer Discov. 1 mai 2016;6(5):492\u2011500.","DOI":"10.1158\/2159-8290.CD-15-1335"},{"key":"4081_CR8","doi-asserted-by":"crossref","unstructured":"Martin-Romano P, Baldini C, Postel-Vinay S. How Much Can We Bet on Activity of BET Inhibitors Beyond NUT\u2013Midline Carcinoma? JNCI Cancer Spectr. 6 nov 2019;4(2):pkz092.","DOI":"10.1093\/jncics\/pkz092"},{"key":"4081_CR9","doi-asserted-by":"crossref","unstructured":"Di Carlo D, Annereau M, Vignes M, Denis L, Epaillard N, Dumont S, et al. Real life data of ONC201 (dordaviprone) in pediatric and adult H3K27-altered recurrent diffuse midline glioma: Results of an international academia-driven compassionate use program. Eur J Cancer. 5 f\u00e9vr 2025;216:115165.","DOI":"10.1016\/j.ejca.2024.115165"},{"key":"4081_CR10","unstructured":"Protocole d\u2019utilisation therapeutique Birabresib. 2025. Available at https:\/\/ansm.sante.fr\/actualites\/gustave-roussy-et-lansm-permettent-a-des-patients-atteints-dun-cancer-rare-un-acces-securise-a-un-nouveau-traitemen."},{"key":"4081_CR11","doi-asserted-by":"crossref","unstructured":"Degrassat-Th\u00e9as A, Bocquet F, Sin\u00e8gre M, Peign\u00e9 J, Paubel P. The \u201cTemporary Recommendations for Use\u201d: A dual-purpose regulatory framework for off-label drug use in France. Health Policy. 1 nov 2015;119(11):1399\u2011405.","DOI":"10.1016\/j.healthpol.2015.09.003"},{"key":"4081_CR12","doi-asserted-by":"crossref","unstructured":"Carlo DD, Annereau M, Yoldjian I, Vassal G, Grill J. An academia-driven compassionate use program for patients with recurrent H3K27-altered diffuse midline glioma: a new way to access innovation when clinical trials are lacking. Annals of Oncology. 1 sept 2023;34(9):826\u20117.","DOI":"10.1016\/j.annonc.2023.06.012"},{"key":"4081_CR13","doi-asserted-by":"crossref","unstructured":"Annereau M, Secretan PH, Vignes M, Ramos S, Grill J, Bizien T, et al. Development of a pediatric oral solution of ONC201 using nicotinamide to enhance solubility and stability. Int J Pharm. 25 d\u00e9c 2024;667(Pt B):124965.","DOI":"10.1016\/j.ijpharm.2024.124965"},{"key":"4081_CR14","doi-asserted-by":"crossref","unstructured":"Chemistry, Manufacture and Control. In: Biopharmaceutical Processing [Internet]. Elsevier; 2018 [cit\u00e9 7 janv 2026]. p. 1105\u201136. Disponible sur: https:\/\/www.sciencedirect.com\/science\/chapter\/edited-volume\/abs\/pii\/B9780081006238000505","DOI":"10.1016\/B978-0-08-100623-8.00050-5"},{"key":"4081_CR15","doi-asserted-by":"crossref","unstructured":"Yu LX, Amidon G, Khan MA, Hoag SW, Polli J, Raju GK, et al. Understanding Pharmaceutical Quality by Design. AAPS J. 23 mai 2014;16(4):771\u201183.","DOI":"10.1208\/s12248-014-9598-3"},{"key":"4081_CR16","doi-asserted-by":"crossref","unstructured":"Noviana E, Indrayanto G, Rohman A. Advances in Fingerprint Analysis for Standardization and Quality Control of Herbal Medicines. Front Pharmacol. 2 juin 2022;13:853023.","DOI":"10.3389\/fphar.2022.853023"},{"key":"4081_CR17","doi-asserted-by":"crossref","unstructured":"Balaji N, Chinnapattu M, Dixit A, Sahu P, P S S, Mullangi R. Validation of an enantioselective LC-MS\/MS method to quantify enantiomers of (\u00b1)-OTX015 in mice plasma: Lack of in vivo inversion of (-)-OTX015 to its antipode. Biomed Chromatogr. avr 2017;31(4).","DOI":"10.1002\/bmc.3853"},{"key":"4081_CR18","doi-asserted-by":"crossref","unstructured":"Nowak RP, Ragosta L, Huerta F, Liu H, Ficarro SB, Cruite JT, et al. Development of a covalent cereblon-based PROTAC employing a fluorosulfate warhead. RSC Chem Biol. 1 nov 2023;4(11):906\u201112.","DOI":"10.1039\/D3CB00103B"},{"key":"4081_CR19","doi-asserted-by":"crossref","unstructured":"Loftsson T. 1,4-Benzodiazepines: Chemical stability and cyclodextrin solubilization. Journal of Drug Delivery Science and Technology. 1 d\u00e9c 2021;66:102936.","DOI":"10.1016\/j.jddst.2021.102936"},{"issue":"20","key":"4081_CR20","doi-asserted-by":"publisher","first-page":"8968","DOI":"10.3390\/su16208968","volume":"16","author":"M G\u00f6kelma","year":"2024","unstructured":"G\u00f6kelma M, Diaz F, \u00c7apk\u0131n \u0130Y, Friedrich B. A Viability Study of Thermal Pre-Treatment for Recycling of Pharmaceutical Blisters. Sustainability janv. 2024;16(20):8968.","journal-title":"Sustainability janv"},{"key":"4081_CR21","doi-asserted-by":"crossref","unstructured":"Campbell JM, Grinias K, Facchine K, Igne B, Clawson J, Peterson J, et al. Analysis of unstable degradation impurities of a benzodiazepine and their quantification without isolation using multiple linear regression. J Pharm Biomed Anal. 15 avr 2019;167:1\u20116.","DOI":"10.1016\/j.jpba.2019.01.028"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04081-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-026-04081-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04081-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T15:31:26Z","timestamp":1781537486000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-026-04081-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["4081"],"URL":"https:\/\/doi.org\/10.1007\/s11095-026-04081-9","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"16 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interest that could have influenced the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}